You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 286 No. 17, November 7, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Hematology/ Hematologic Malignancies
 •Anemias
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Challenge of Painful Crisis in Sickle Cell Disease

Ronald L. Nagel, MD

JAMA. 2001;286:2152-2153.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Acute painful crisis in sickle cell disease is a frequent complication and considerably diminishes the quality of life of patients with this disease.1 The pain of sickle cell crisis is one of the most intense in medicine—it has been compared with that of a severe toothache—and affects the extremities, abdomen, lower back, or multiple sites simultaneously. The unpredictability of such painful episodes adds to their discomfort.

Some major precipitating factors and aggravating circumstances that contribute to the complex pathophysiology of acute painful crisis include infection, dehydration, excessive exercise,2 emotional disturbances, or stressful environments. Furthermore, lack of prompt and individualized acute pain treatment increases hospitalization rates as well as the duration and intensity of painful episodes.3-4

Even though sickle cell disease was discovered in 19105 and defined at the molecular level in the 1950s,6-7 it was not until 1995 that a proven ameliorating therapy was discovered. In . . . [Full Text of this Article]

Author Affiliation: Division of Hematology, Albert Einstein College of Medicine/Montefiore Hospital, Bronx, NY.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease: A Randomized Controlled Trial
Eugene P. Orringer, James F. Casella, Kenneth I. Ataga, Mabel Koshy, Patricia Adams-Graves, Lori Luchtman-Jones, Ted Wun, Masayo Watanabe, Frank Shafer, Abdullah Kutlar, Miguel Abboud, Martin Steinberg, Brian Adler, Paul Swerdlow, Carol Terregino, Suzanne Saccente, Beatrice Files, Samir Ballas, Robert Brown, Slawomir Wojtowicz-Praga, and J. Michael Grindel
JAMA. 2001;286(17):2099-2106.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.